Drugs / ABI-H2158
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04142762 | Oct 2019 → Jan 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04083716 | Sep → Oct 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03714152 | Nov 2018 → Nov 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04398134 | Aug 2020 → Oct 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-H2158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04142762 ↗ |
| Route | Oral | “ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days” NCT03714152 ↗ |